Journal article icon

Journal article

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.

Abstract:

BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not recommended by the England and Wales National Institute for Health and Clinical Excellence. However, there is little...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1186/1745-6215-10-57

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Nuffield Department of Population Health, NPEU
Role:
Author
Expand authors...
Medical Research Council More from this funder
Alzheimer's Society More from this funder
Publisher:
BioMed Central Publisher's website
Journal:
Trials Journal website
Volume:
10
Issue:
1
Pages:
57
Chapter number:
ARTN 57
Publication date:
2009-01-01
DOI:
EISSN:
1745-6215
ISSN:
1745-6215
URN:
uuid:b9f73fa7-7012-44e1-873d-e9e835a2ebcb
Source identifiers:
112086
Local pid:
pubs:112086

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP